Although most findings suggest a relatively good prognosis in MDS-RS patients with SF3B1 mutations, the prognosis in MDS patients containing poor predictors remains unsatisfactory, and effective biomarkers to guide their prognostic significance remain to be elucidated in clinical application. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.